Skip to main content
NCBI home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jun 7;8(4):353–360. doi: 10.1111/j.1527-3458.2002.tb00233.x

BMS‐204352: A Potassium Channel Opener Developed for the Treatment of Stroke

Bo Skaaning Jensen 1,✉
PMCID: PMC6741660  PMID: 12481191

ABSTRACT

During ischemic stroke, a fatal biochemical cascade that results in neuronal hyperexcitability is initiated when neurons at risk are exposed to excessive excitatory amino acids and pathologically high levels of intracellular calcium (Ca2+). Therefore, neuroprotectants including NMDA‐antagonists and blockers of voltage‐gated Ca2+ channels have been proposed as novel strategies for stroke treatment. Since potassium channels are key players in the control of neuronal excitability, and activation of neuronal potassium channels decrease excitability and neurotransmitter release, a novel approach for targeting acute ischemic stroke has been to develop openers of neuronal potassium channels. Bristol‐Myers Squibb is developing BMS‐204352, a fluoro‐oxindole potassium channel opener, as a potential neuroprotectant for the treatment of acute ischemic stroke. BMS‐203252 is a potent and effective opener of two important subtypes of neuronal potassium channels, the calcium‐activated, big‐conductance potassium channels (KCa channels) and voltage‐dependent, non‐inactivating potassium channels known as KCNQ channels. BMS‐204352 (0.3 mg/kg, i.v.) significantly reduced cortical infarct volume in a model of permanent occlusion of the middle cerebral artery (MCA) in spontaneous hypertensive rats (SHR), as compared to vehicle when administered 2 h post‐occlusion. At doses from 1 μg/kg to 1 mg/kg i.v., BMS‐204352 produced a significant reduction in cortical infarct volume in normotensive Wistar rats. In healthy humans, single and multiple i.v. doses of BMS‐204352 (0.001 to 0.2 mg/kg) were safe, well‐tolerated and without psychomotor function effects. Multiple doses of BMS‐204352 (0.1–2 mg/kg i.v.) administered within 48 h after stroke onset were well tolerated in patients in Phase II studies, designed to evaluate safety, tolerability and pharmacokinetics. No clinically significant differences in organ toxicity or adverse effects were found, and total clearance and volume of distribution were independent of dose. BMS‐204352 failed to show superior efficacy in acute stroke patients compared to placebo in a Phase III study that included 1978 patients at 200 centers worldwide.

Keywords: BK channel, Ca2+‐Activated K+ channel, Cerebral ischemia, hSlo channel, Maxi‐K channel, Neuronal hyperexcitability

Full Text

The Full Text of this article is available as a PDF (91.8 KB).

References

  1. . American College of Physicians and the Investigators of the PORT Study , 1994. Guidelines for medical treatment for stroke prevention. Ann Intern Med 1994;121:54–55. [DOI] [PubMed] [Google Scholar]
  2. 2. Bozik ME, Smith JM, Douglass A, et al. POST: double‐blind placebo controlled, safety and efficacy trial of intravenous BMS‐204352 in patients with acute stroke. Stroke 2000;31:1–270. 10625706 [Google Scholar]
  3. 3. Bozik ME, Smith JM, Sullivan MA, Braga JM, Warach S, Luby M. POST: Double‐blind placebo controlled, safety and efficacy trial of intravenous BMS‐204352 in patients with acute stroke. Stroke 2000;31:1–269. 10625706 [Google Scholar]
  4. 4. Cheney JA, Weisser JD, Bareyre FM, et al. The maxi‐K channel opener BMS‐204352 attenuates regional cerebral edema and neurologic motor impairment after experimental brain injury. J Cereb Blood Flow Metab 2001;21 (4): 396–403. [DOI] [PubMed] [Google Scholar]
  5. 5. Choi DW. Calcium: Still center‐stage in hypoxic‐ischemic neuronal death. Trends Neurosci 1995;8 (2): 58–60. [PubMed] [Google Scholar]
  6. 6. Choi DW. Excitotoxic cell death. J Neurobiol 1992;23 (9): 1261–1276. [DOI] [PubMed] [Google Scholar]
  7. 7. Clark WM, Madden KP, Rothlein R, et al. Reduction of central nervous system ischemic injury by monoclonal antibody to intercellular adhesion molecule. J Neurosurg 1991;75:623–627. [DOI] [PubMed] [Google Scholar]
  8. 8. De Keyser J, Sutter G, Luiten PG. Clinical trials with neuroprotective drugs in acute ischaemic stroke: Are we doing the right thing Trends Neurosci 1999;22:535–540. [DOI] [PubMed] [Google Scholar]
  9. 9. Dupuis DS, Schrøder RL, Jespersen T, et al. Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS‐204352. Eur J Pharmacol 2002;In press. [DOI] [PubMed] [Google Scholar]
  10. 10. Fayad O, Caplik J, Culligan N, et al. Cerebrovasc Dis 2000;10(Suppl 2): 71. [Google Scholar]
  11. 11. Frantz SW, Srinivas N, Dominick M, Kelly W, Sanderson T, Schilling B. Safety assessement of BMS‐204352, a novel therapeutic agent for the treatment of stroke. Eur J Neurol 2000;7(Suppl 3): P3017. [Google Scholar]
  12. 12. Gold M, Fulmor IE, Srinivas N, Uderman H, Salazar D. BMS‐204352: A novel maxi‐K potassium opener for the treatment of stroke: Safety and clinical pharmacology in healthy subjects. Ann Neurol 2000;48:3–19. [Google Scholar]
  13. 13. Gribkoff VK, Starrett JE Jr, Dworetzky SI, et al. Targeting acute ischemic stroke with a calcium‐sensitive opener of maxi‐K potassium channels. Nature Med 2001;(4): 471–477. [DOI] [PubMed] [Google Scholar]
  14. 14. Hallenbeck JM, Dutka AJ. Background review and current concepts of reperfusion injury. Arch Neurol 1990;47:1245–1254. [DOI] [PubMed] [Google Scholar]
  15. 15. Hewawasan P, Gribkoff V, Dworetsky S, Ortiz A, Starrett J, et al. Discovery of openers of large‐conductance, calcium activated potassium (maxi‐K) channels: A new approach to stroke neuroprotection. ACS 219th 2000. San Francisco MEDI 320.
  16. 16. Hewawasam P, Meanwell NA, Gribkoff VK. 3‐substituted oxindole derivatives as potassium channel modulators 1.1996. Bristol Myers Squibb Co. US Pat. 05565483.
  17. 17. Jentsch TJ. Neuronal KCNQ potassium channels: physiology and role in disease. Nat Rev Neurosci 2000;1 (1): 21–30. [DOI] [PubMed] [Google Scholar]
  18. 18. Kristian T, Siesjo BK. Calcium in ischemic cell death. Stroke 1998;29 (3): 705–718. [DOI] [PubMed] [Google Scholar]
  19. 19. Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med 1999;340 (23): 1781–1787. [DOI] [PubMed] [Google Scholar]
  20. 20. McKay MC, Dworetzky SI, Meanwell NA, et al. Opening of large‐conductance calcium‐activated potassium channels by the substituted benzimidazolone NS004. J Neurophysiol 1994;71 (5): 1873–1882. [DOI] [PubMed] [Google Scholar]
  21. 21. Olesen SP, Munch E, Moldt P, Drejer J. Selective activation of Ca2+‐dependent K+ channels by novel benzimidazolone. Eur J Pharmacol 1994;251 (1): 53–59. [DOI] [PubMed] [Google Scholar]
  22. 22. Olesen SP, Munch E, Watjen F, Drejer J. NS004 — an activator of Ca2+‐dependent K+ channels in cerebellar granule cells. NeuroReport 1994;5 (8): 1001–1004. [DOI] [PubMed] [Google Scholar]
  23. 23. Pendri YR, Martinez EJ, Thottathil JK, Hewawasam P. Preparation of 3‐fluoro oxindole derivatives. 1998. Bristol Myers Squibb Co US. Pat. 05808095.
  24. 24. Rundfeldt C. The new anticonvulsant retigabine (D‐23129) acts as an opener of K+ channels in neuronal cells. Eur J Pharmacol 1997;336 (2–3): 243–249. [DOI] [PubMed] [Google Scholar]
  25. 25. Salazar DE, Fulmor IE, Srinivas N, Gold M, Uderman H. BMS‐204352 — a novel maxi‐K potassium opener for the treatment of stroke: Safety and clinical pharmacology in healthy subjects. Eur J Neurol 2000;7(Suppl 3): S40. [Google Scholar]
  26. 26. Schrøder RL, Jespersen T, Christophersen P, Strøbæk D, Jensen BS, Olesen SP. KCNQ4 channel activation by BMS‐204352 and retigabine. Neuropharmacology 2001;40 (7): 888–898. [DOI] [PubMed] [Google Scholar]
  27. 27. Shieh CC, Coghlan M, Sullivan JP, Gopalakrishnan M. Potassium channels: Molecular defects, diseases, and therapeutic opportunities. Pharmacol Rev 2000;52 (4): 557–594. [PubMed] [Google Scholar]
  28. 28. Starrett JE, Kiesewetter DO, Jagoda EM, et al. Brain uptake and biodistribution studies in rats of the maxi‐K channel opener BMS‐204352: A potential neuroprotectant for the treatment of acute stroke. Ann Neurol 2000;48:3–153. [Google Scholar]
  29. 29. Strøbæk D, Christophersen P, Holm NR, et al. Modulation of the Ca2+‐dependent K+ channel, hslo, by the substituted diphenylurea NS1608, paxilline and internal Ca2+ . Neuropharmacology 1996;35 (7): 903–914. [DOI] [PubMed] [Google Scholar]
  30. 30. Sudlow CL, Warlow CP. Comparable studies of the incidence of stroke and its pathological types: results from an international collaboration. International Stroke Incidence Collaboration. Stroke 1997;28:491–499. [DOI] [PubMed] [Google Scholar]
  31. 31. Zipfel GJ, Lee JM, Choi DW. Reducing calcium overload in the ischemic brain. N Engl J Med 1999;341 (20): 1543–1544. [DOI] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES